Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients

Published:2020-12-08 Issue:6 Volume:47 Page:362-365
ISSN:1542-2321
Container-title:Eye & Contact Lens: Science & Clinical Practice
language:en
Short-container-title:

Author:

Bausell Rebecca B.,Soleimani Arshia,Vinnett Alfred,Baroni Mariana D.,Staub Sheila A.,Binion Katrina,Jeng Bennie H.,Badros Ashraf Z.,Munir Wuqaas M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology

Reference14 articles.

1. Treatment options for relapsed and refractory multiple myeloma;Nooka;Blood,2015

2. Abnormal corneal lesions induced by Trastuzumab Emtansine: An antibody-drug conjugate for breast cancer;Tsuda;Cornea,2016

3. Ocular adverse events associated with antibody-drug conjugates in human clinical trials;Eaton;J Ocul Pharmacol Ther,2015

4. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma;Tannir;Invest New Drugs,2014

5. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma;Younes;J Clin Oncol,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?;Journal of Ocular Pharmacology and Therapeutics;2024-07-08

2. Visualization of Keratopathy Associated With the Antibody–Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma;Cornea;2024-06-18

3. Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs);Current Ophthalmology Reports;2024-03-25

4. Antibody-Drug Conjugates and Ocular Toxicity;Journal of Ocular Pharmacology and Therapeutics;2023-12-01

5. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma;Expert Opinion on Drug Safety;2023-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3